

BGI-Shenzhen extends tender offer for Complete Genomics

24 April 2013 | News | By BioSpectrum Bureau



Singapore: BGI-Shenzhen (BGI) announced that it, through its wholly owned subsidiary Beta Acquisition, has extended its all cash tender offer to purchase all outstanding shares of common stock of Complete Genomics to 12:00 am ET on Monday, January 7, 2013. The Offer was previously scheduled to expire at 12:00 am ET on Monday, December 31, 2012.

Except for the extension of the Offer expiration date, all other terms and conditions of the Offer remain unchanged. The Depositary for the Offer has indicated that, as of the close of business on December 28, 2012, approximately 17,822,265 shares, or approximately 50 percent, of common stock of Complete have been validly tendered in and not withdrawn from the Offer, including shares of common stock of Complete subject to guaranteed delivery procedures.

BGI's financial advisor is Citi, and its legal counsel is O'Melveny & Myers. Complete's financial adviser is Jefferies & Company, and its legal counsel is Latham & Watkins.